Clinical Research

Characteristics of Patients with a Complete Response Treated with Dabrafenib plus Trametinib Combination Therapy: Findings from Pooled COMBI-d and COMBI-v 5-Year Analysis
By Caroline Robert, MD, PhD; Jean-Jacques Grob; Daniil Stroyakovskiy; Boguslawa Karaszewska; Axel Hauschild, MD; Evgeny Levchenko; Vanna Chiarion Sileni, MD; Jacob Schachter, MD; Claus Garbe; Igor Bondarenko; Paul Nathan; Antoni Ribas; Michael A. Davies; Keith Flaherty; Paul Burgess; Monique Tan; Eduard Gasal, MD; Dirk Schadendorf, MD; Georgina V. Long, MD, PhD
Clinical Research, AONN+ Conference Abstracts
November 2020 Vol 11, No 11
Two large phase 3 studies (COMBI-d [NCT01584648] and COMBI-v [NCT01597908]) evaluated the efficacy and safety of oral dabrafenib 150 mg twice daily plus trametinib 2 mg once daily (D+T) as first-line therapy in patients (pts) with BRAF V600E- or V600K-mutant unresectable or metastatic cutaneous melanoma.
Improving Quality of Cancer Care by Integrating Considerations of Shared Importance to Patients and Family Caregivers into Clinical Pathway Platforms
By Dena Schulman-Green, PhD; Emily Cherlin, PhD, MSW; Renee Capasso, BS; Sarah S. Mougalian, MD; Shiyi Wang, MD, PhD; Cary P. Gross, MD; Preeti S. Bajaj, PhD; Katherine Eakle, PharmD; Sharmi Patel, PharmD; Kerin Adelson, MD
Clinical Research, AONN+ Conference Abstracts
November 2020 Vol 11, No 11
Clinical pathways have increasingly been incorporated into cancer care, aiming to encourage high-quality, evidence-based care while minimizing costs; however, clinical pathways infrequently incorporate patient and family perspectives, limiting patient-centeredness and value for shared decision-making.
Nursing Experience in Patients with Chronic Lymphocytic Leukemia Receiving First-Line Ibrutinib: Five Years of Follow-Up from the Phase 3 RESONATE-2 Study
By Jillian Settlemire, RN; Edythe M. Greenberg, PhD, RN, FNP-BC; Indu Lal, MD; Carlos Amaya-Chanaga, MD; Jan A. Burger, MD, PhD; Steven Coutre, MD
Clinical Research, AONN+ Conference Abstracts
November 2020 Vol 11, No 11
Ibrutinib is the only once-daily Bruton tyrosine kinase inhibitor that has shown significant progression-free survival (PFS) and overall survival (OS) benefits in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) across multiple randomized phase 3 studies.
Acalabrutinib vs Rituximab plus Idelalisib or Bendamustine by Investigator Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Phase 3 ASCEND Study
By Paolo Ghia, MD; Andrzej Pluta, MD; Malgorzata Wach, MD; Daniel Lysak, MD; Tomas Kozak, MD; Martin Simkovic, MD; Polina Kaplan, MD; Iryna Kraychok, MD; Arpad Illes, MD; Javier de la Serna, MD; Sean Dolan, MD; Philip Campbell, MD; Gerardo Musuraca, MD; Abraham Jacob, MD; Eric J. Avery, MD; Jae Hoon Lee, MD; Tianling Chen, MD; Wei Liang, PhD; Priti Patel, MD; Wojciech Jurczak, MD
AONN+ Conference Abstracts, Clinical Research
November 2019 Vol 10, No 11
Acalabrutinib is a highly selective, potent, covalent Bruton tyrosine kinase inhibitor that has shown clinical benefit in patients with relapsed/refractory (RR) chronic lymphocytic leukemia (CLL).

Page 2 of 6

Journal of Oncology Navigation & Survivorship

Connect with Us

 
 

Contact Us | Editorial Board

Amplity

© Amplity, Inc. All rights reserved.

JONS

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
    Profession or Role
    Primary Specialty or Disease State
    Country

Back to Top

Amplity © Amplity, Inc. All rights reserved.

We Value Your Feedback! Tell Us How You Consume Content

Your feedback will help us tailor our content to better meet your needs and preferences.

*First Name
*Last Name
*Email
*What's your favorite format for experiencing our content?